Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 443.64
ABAX's Cash to Debt is ranked higher than
71% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. ABAX: 443.64 )
Ranked among companies with meaningful Cash to Debt only.
ABAX' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: 184.82 Max: No Debt
Current: 443.64
Equity to Asset 0.88
ABAX's Equity to Asset is ranked higher than
89% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. ABAX: 0.88 )
Ranked among companies with meaningful Equity to Asset only.
ABAX' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.86 Max: 0.9
Current: 0.88
0.48
0.9
Interest Coverage 1534.90
ABAX's Interest Coverage is ranked higher than
67% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.70 vs. ABAX: 1534.90 )
Ranked among companies with meaningful Interest Coverage only.
ABAX' s Interest Coverage Range Over the Past 10 Years
Min: 27.18  Med: N/A Max: No Debt
Current: 1534.9
F-Score: 7
Z-Score: 22.17
M-Score: -2.35
WACC vs ROIC
11.82%
28.81%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 20.37
ABAX's Operating margin (%) is ranked higher than
89% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.14 vs. ABAX: 20.37 )
Ranked among companies with meaningful Operating margin (%) only.
ABAX' s Operating margin (%) Range Over the Past 10 Years
Min: 12.42  Med: 16.77 Max: 26.55
Current: 20.37
12.42
26.55
Net-margin (%) 15.54
ABAX's Net-margin (%) is ranked higher than
89% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. ABAX: 15.54 )
Ranked among companies with meaningful Net-margin (%) only.
ABAX' s Net-margin (%) Range Over the Past 10 Years
Min: 8.36  Med: 11.53 Max: 15.54
Current: 15.54
8.36
15.54
ROE (%) 14.59
ABAX's ROE (%) is ranked higher than
83% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.49 vs. ABAX: 14.59 )
Ranked among companies with meaningful ROE (%) only.
ABAX' s ROE (%) Range Over the Past 10 Years
Min: 7.67  Med: 11.53 Max: 16.35
Current: 14.59
7.67
16.35
ROA (%) 12.73
ABAX's ROA (%) is ranked higher than
91% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.98 vs. ABAX: 12.73 )
Ranked among companies with meaningful ROA (%) only.
ABAX' s ROA (%) Range Over the Past 10 Years
Min: 6.77  Med: 10.01 Max: 14.32
Current: 12.73
6.77
14.32
ROC (Joel Greenblatt) (%) 57.14
ABAX's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.85 vs. ABAX: 57.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABAX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 31.27  Med: 42.82 Max: 65.45
Current: 57.14
31.27
65.45
Revenue Growth (3Y)(%) 5.80
ABAX's Revenue Growth (3Y)(%) is ranked higher than
59% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. ABAX: 5.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABAX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.5  Med: 13.6 Max: 32.8
Current: 5.8
4.5
32.8
EBITDA Growth (3Y)(%) -1.50
ABAX's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. ABAX: -1.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABAX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.5  Med: 24.3 Max: 222.4
Current: -1.5
-1.5
222.4
EPS Growth (3Y)(%) -0.70
ABAX's EPS Growth (3Y)(%) is ranked higher than
54% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. ABAX: -0.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABAX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.2  Med: 6.3 Max: 159.6
Current: -0.7
-59.2
159.6
» ABAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ABAX Guru Trades in Q4 2015

Jim Simons 214,671 sh (+103.30%)
PRIMECAP Management 2,346,000 sh (+0.04%)
Joel Greenblatt Sold Out
Steven Cohen 51,200 sh (-24.15%)
Columbia Wanger 640,699 sh (-25.15%)
» More
Q1 2016

ABAX Guru Trades in Q1 2016

Paul Tudor Jones 9,600 sh (New)
PRIMECAP Management 2,347,500 sh (+0.06%)
Columbia Wanger Sold Out
Steven Cohen Sold Out
Jim Simons 204,519 sh (-4.73%)
» More
Q2 2016

ABAX Guru Trades in Q2 2016

Joel Greenblatt 53,899 sh (New)
Jim Simons 226,871 sh (+10.93%)
Paul Tudor Jones Sold Out
PRIMECAP Management 2,333,000 sh (-0.62%)
» More
Q3 2016

ABAX Guru Trades in Q3 2016

PRIMECAP Management 2,323,000 sh (-0.43%)
Jim Simons 169,900 sh (-25.11%)
Joel Greenblatt 40,267 sh (-25.29%)
» More
» Details

Insider Trades

Latest Guru Trades with ABAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:MYGN, NAS:ALOG, NAS:AXDX, NAS:KANG, NAS:GHDX, NAS:MEDP, NAS:FMI, NAS:QDEL, NAS:NEO, NAS:VIVO, NAS:EXAS, NYSE:ARA, NAS:NTRA, NAS:BEAT, NAS:NRCIA, NAS:NVDQ, NAS:HSKA, NAS:LNTH, NAS:ONVO, NAS:SRDX » details
Traded in other countries:AXS.Germany,
Abaxis Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements.

Abaxis Inc is a California corporation and was incorporated in 1989. The Company is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. Its products and services include point-of-care diagnostic instruments and consumables used in the medical market and point-of-care diagnostic instruments and consumables used in the veterinary market. The Company manages its business in two reportable business segments, the medical market and the veterinary market, which are based on the diagnostic products sold and services provided by market and customer group. For products that it sells that are not specifically identified to any particular business segment, it categorizes the revenue as Other. The Company's products sold to the medical market are used by medical specialties requiring real time results to enable rapid clinical decisions in the area of human diagnostics. Its point-of-care products in the medical market are comprised of its Piccolo chemistry analyzers and consumable products. In the veterinary market, its VetScan products serves a customer group consisting of companion animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies and private research laboratories. Its product and service offerings in the veterinary market include VetScan Point-of-Care Blood Chemistry Instruments, VetScan Profiles, Hematology Instruments and Consumables, VSpro Specialty Analyzers and Consumables, i-STAT Instruments and Consumables, Rapid Tests, and Abaxis Veterinary Reference Laboratories services. Its Other segment include sale of products using its patented Orbos Discrete Lyophilization Process (the Orbos process) to companies for other applications. The Orbos process involves flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The Orbos beads are stable in dry form and dissolve rapidly in aqueous solutions. The dry reagents used in its reagent discs are produced using the Orbos process. This process allows the production of a precise amount of active chemical ingredient in the form of a soluble bead. The Company's competitors in the point-of-care human medical diagnostic market are Inverness Medical Switzerland GmbH, now known as Alere Switzerland GmbH ("Alere"), Alfa Wassermann S.P.A., Johnson & Johnson, Ortho-Clinical Diagnostics, Inc. and F. Hoffmann-La Roche Ltd. The Company's Piccolo products are in vitro diagnostic medical devices subject to regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act (FDCA).

Ratios

vs
industry
vs
history
P/E(ttm) 33.07
ABAX's P/E(ttm) is ranked lower than
57% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.96 vs. ABAX: 33.07 )
Ranked among companies with meaningful P/E(ttm) only.
ABAX' s P/E(ttm) Range Over the Past 10 Years
Min: 20.75  Med: 43.35 Max: 75.53
Current: 33.07
20.75
75.53
Forward P/E 35.21
ABAX's Forward P/E is ranked lower than
74% of the 47 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.70 vs. ABAX: 35.21 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 33.29
ABAX's PE(NRI) is ranked lower than
59% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.55 vs. ABAX: 33.29 )
Ranked among companies with meaningful PE(NRI) only.
ABAX' s PE(NRI) Range Over the Past 10 Years
Min: 20.75  Med: 44.04 Max: 72.56
Current: 33.29
20.75
72.56
Price/Owner Earnings (ttm) 45.96
ABAX's Price/Owner Earnings (ttm) is ranked lower than
73% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.54 vs. ABAX: 45.96 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ABAX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 16.03  Med: 52.82 Max: 352.63
Current: 45.96
16.03
352.63
P/B 4.50
ABAX's P/B is ranked lower than
66% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.35 vs. ABAX: 4.50 )
Ranked among companies with meaningful P/B only.
ABAX' s P/B Range Over the Past 10 Years
Min: 2.19  Med: 4.64 Max: 8.07
Current: 4.5
2.19
8.07
P/S 5.10
ABAX's P/S is ranked lower than
67% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. ABAX: 5.10 )
Ranked among companies with meaningful P/S only.
ABAX' s P/S Range Over the Past 10 Years
Min: 2.48  Med: 5.04 Max: 8.56
Current: 5.1
2.48
8.56
PFCF 42.31
ABAX's PFCF is ranked lower than
70% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.43 vs. ABAX: 42.31 )
Ranked among companies with meaningful PFCF only.
ABAX' s PFCF Range Over the Past 10 Years
Min: 21.4  Med: 45.69 Max: 101.82
Current: 42.31
21.4
101.82
POCF 32.50
ABAX's POCF is ranked lower than
76% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.33 vs. ABAX: 32.50 )
Ranked among companies with meaningful POCF only.
ABAX' s POCF Range Over the Past 10 Years
Min: 17.14  Med: 33.76 Max: 79.01
Current: 32.5
17.14
79.01
EV-to-EBIT 21.61
ABAX's EV-to-EBIT is ranked lower than
51% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.82 vs. ABAX: 21.61 )
Ranked among companies with meaningful EV-to-EBIT only.
ABAX' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.6  Med: 26.45 Max: 46.7
Current: 21.61
10.6
46.7
EV-to-EBITDA 18.80
ABAX's EV-to-EBITDA is ranked lower than
61% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.42 vs. ABAX: 18.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.7  Med: 21.6 Max: 39.3
Current: 18.8
8.7
39.3
PEG 2.47
ABAX's PEG is ranked higher than
55% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. ABAX: 2.47 )
Ranked among companies with meaningful PEG only.
ABAX' s PEG Range Over the Past 10 Years
Min: 0.7  Med: 2.34 Max: 11.8
Current: 2.47
0.7
11.8
Shiller P/E 56.66
ABAX's Shiller P/E is ranked lower than
72% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.55 vs. ABAX: 56.66 )
Ranked among companies with meaningful Shiller P/E only.
ABAX' s Shiller P/E Range Over the Past 10 Years
Min: 38.73  Med: 59.94 Max: 240.7
Current: 56.66
38.73
240.7
Current Ratio 7.71
ABAX's Current Ratio is ranked higher than
90% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. ABAX: 7.71 )
Ranked among companies with meaningful Current Ratio only.
ABAX' s Current Ratio Range Over the Past 10 Years
Min: 1.54  Med: 5.97 Max: 9.82
Current: 7.71
1.54
9.82
Quick Ratio 6.47
ABAX's Quick Ratio is ranked higher than
90% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. ABAX: 6.47 )
Ranked among companies with meaningful Quick Ratio only.
ABAX' s Quick Ratio Range Over the Past 10 Years
Min: 1.12  Med: 4.82 Max: 8.45
Current: 6.47
1.12
8.45
Days Inventory 129.04
ABAX's Days Inventory is ranked lower than
64% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 85.13 vs. ABAX: 129.04 )
Ranked among companies with meaningful Days Inventory only.
ABAX' s Days Inventory Range Over the Past 10 Years
Min: 100.6  Med: 121.74 Max: 136.06
Current: 129.04
100.6
136.06
Days Sales Outstanding 56.94
ABAX's Days Sales Outstanding is ranked higher than
59% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.09 vs. ABAX: 56.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.27  Med: 71.25 Max: 80.73
Current: 56.94
52.27
80.73
Days Payable 26.55
ABAX's Days Payable is ranked lower than
81% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.24 vs. ABAX: 26.55 )
Ranked among companies with meaningful Days Payable only.
ABAX' s Days Payable Range Over the Past 10 Years
Min: 25.83  Med: 33.93 Max: 65.46
Current: 26.55
25.83
65.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.97
ABAX's Dividend Yield is ranked lower than
60% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.08 vs. ABAX: 0.97 )
Ranked among companies with meaningful Dividend Yield only.
ABAX' s Dividend Yield Range Over the Past 10 Years
Min: 0.21  Med: 0.81 Max: 1.11
Current: 0.97
0.21
1.11
Dividend Payout 0.30
ABAX's Dividend Payout is ranked higher than
80% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.25 vs. ABAX: 0.30 )
Ranked among companies with meaningful Dividend Payout only.
ABAX' s Dividend Payout Range Over the Past 10 Years
Min: 0.24  Med: 0.36 Max: 0.63
Current: 0.3
0.24
0.63
Forward Dividend Yield 1.10
ABAX's Forward Dividend Yield is ranked lower than
57% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.24 vs. ABAX: 1.10 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.97
ABAX's Yield on cost (5-Year) is ranked lower than
68% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.39 vs. ABAX: 0.97 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABAX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.21  Med: 0.81 Max: 1.11
Current: 0.97
0.21
1.11
3-Year Average Share Buyback Ratio -0.40
ABAX's 3-Year Average Share Buyback Ratio is ranked higher than
78% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. ABAX: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.7  Med: -2.8 Max: 0.4
Current: -0.4
-9.7
0.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.35
ABAX's Price/Net Cash is ranked lower than
56% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.33 vs. ABAX: 10.35 )
Ranked among companies with meaningful Price/Net Cash only.
ABAX' s Price/Net Cash Range Over the Past 10 Years
Min: 5.92  Med: 14.86 Max: 300
Current: 10.35
5.92
300
Price/Net Current Asset Value 5.96
ABAX's Price/Net Current Asset Value is ranked higher than
53% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. ABAX: 5.96 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ABAX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.41  Med: 7.07 Max: 41.25
Current: 5.96
3.41
41.25
Price/Tangible Book 4.53
ABAX's Price/Tangible Book is ranked lower than
52% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.57 vs. ABAX: 4.53 )
Ranked among companies with meaningful Price/Tangible Book only.
ABAX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.88  Med: 4.91 Max: 36.9
Current: 4.53
2.88
36.9
Price/Projected FCF 2.25
ABAX's Price/Projected FCF is ranked lower than
51% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. ABAX: 2.25 )
Ranked among companies with meaningful Price/Projected FCF only.
ABAX' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.7  Med: 2.68 Max: 201
Current: 2.25
1.7
201
Price/DCF (Earnings Based) 2.02
ABAX's Price/DCF (Earnings Based) is ranked lower than
62% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.74 vs. ABAX: 2.02 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.01
ABAX's Price/Median PS Value is ranked lower than
54% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. ABAX: 1.01 )
Ranked among companies with meaningful Price/Median PS Value only.
ABAX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.31  Med: 0.93 Max: 1.68
Current: 1.01
0.31
1.68
Price/Peter Lynch Fair Value 2.52
ABAX's Price/Peter Lynch Fair Value is ranked higher than
52% of the 27 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.66 vs. ABAX: 2.52 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ABAX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.52  Med: 2.39 Max: 11.04
Current: 2.52
0.52
11.04
Price/Graham Number 2.59
ABAX's Price/Graham Number is ranked higher than
57% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. ABAX: 2.59 )
Ranked among companies with meaningful Price/Graham Number only.
ABAX' s Price/Graham Number Range Over the Past 10 Years
Min: 1.46  Med: 3.03 Max: 10.79
Current: 2.59
1.46
10.79
Earnings Yield (Greenblatt) (%) 4.60
ABAX's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.94 vs. ABAX: 4.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABAX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.1  Med: 3.8 Max: 9.5
Current: 4.6
2.1
9.5
Forward Rate of Return (Yacktman) (%) 15.34
ABAX's Forward Rate of Return (Yacktman) (%) is ranked higher than
70% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.70 vs. ABAX: 15.34 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ABAX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 6.9  Med: 17.2 Max: 44.4
Current: 15.34
6.9
44.4

More Statistics

Revenue (TTM) (Mil) $226.1
EPS (TTM) $ 1.53
Beta1.26
Short Percentage of Float19.36%
52-Week Range $37.71 - 58.15
Shares Outstanding (Mil)22.54

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 232 241
EPS ($) 1.38 1.45
EPS w/o NRI ($) 1.38 1.45
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ABAX

Headlines

Articles On GuruFocus.com
PRIMECAP Adds to Three Stakes in Portfolio Jul 07 2015 
Distribution: A Potentially Under-appreciated Moat Jun 08 2015 
ABAXIS Inc. (ABAX) COO Donald Peter Wood sells 6,460 Shares Mar 08 2011 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 35,000 Shares Dec 10 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 96,000 Shares Dec 08 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 66,029 Shares Dec 07 2010 

More From Other Websites
Abaxis downgraded by Northcoast Nov 30 2016
New Strong Sell Stocks for November 25th Nov 25 2016
Abaxis, Inc. to Present at the 28th Annual Piper Jaffray Healthcare Conference Nov 23 2016
ABAXIS INC Financials Nov 17 2016
ETFs with exposure to ABAXIS, Inc. : November 15, 2016 Nov 15 2016
ABAXIS, Inc. breached its 50 day moving average in a Bullish Manner : ABAX-US : November 14, 2016 Nov 14 2016
Ubiquiti, Abaxis and Walt Disney highlighted as Zacks Bull and Bear of the Day Nov 11 2016
Bear of the Day: Abaxis (ABAX) Nov 11 2016
New Strong Sell Stocks for November 10th Nov 10 2016
Abaxis, Inc. to Present at the Stifel 2016 Healthcare Conference and Canaccord Genuity Medical... Nov 10 2016
ABAXIS INC Files SEC form 10-Q, Quarterly Report Nov 09 2016
Abaxis, Inc. to Present at the Stephens 2016 Fall Investment Conference and Participate in the... Nov 04 2016
Abaxis, Inc. to Present at the 25th Annual Credit Suisse Healthcare Conference Nov 02 2016
ABAXIS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a... Nov 01 2016
Abaxis Declares Quarterly Cash Dividend Oct 28 2016
Abaxis Declares Quarterly Cash Dividend Oct 28 2016
New Strong Sell Stocks for October 27th Oct 27 2016
Abaxis (ABAX) Q2 Earnings & Revenues Miss, Margins Slide Oct 27 2016
ABAXIS, Inc. breached its 50 day moving average in a Bearish Manner : ABAX-US : October 26, 2016 Oct 26 2016
Edited Transcript of ABAX earnings conference call or presentation 25-Oct-16 8:15pm GMT Oct 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)